KYTX
NASDAQ · Biotechnology
Kyverna Therapeutics Inc
$8.87
+0.07 (+0.80%)
Open$8.75
Previous Close$8.80
Day High$8.95
Day Low$8.62
52W High$13.67
52W Low$1.95
Volume—
Avg Volume835.0K
Market Cap562.93M
P/E Ratio—
EPS$-3.65
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
-8.0% upside
Current
$8.87
$8.87
Target
$8.16
$8.16
$5.68
$8.16 avg
$10.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.52M | 81.06M | 62.85M |
| Net Income | -14,424,701 | -12,557,463 | -9,873,224 |
| Profit Margin | -18.6% | -15.5% | -15.7% |
| EBITDA | -20,391,428 | -20,108,436 | -16,996,352 |
| Free Cash Flow | -5,835,314 | -8,946,067 | -4,753,485 |
| Rev Growth | +5.4% | +22.1% | -7.0% |
| Debt/Equity | 0.25 | 0.20 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |